来源：金融界 伟思医疗主营业务：主要从事医疗器械的研发、生产和销售,以研发创新为发展驱动力,持续投入在电刺 激、磁刺激、电生理、康复机器人以及医美能量源等方向的先进技术研发,并完善产品布局。公司致力 于在磁刺激领域成为全球领先供应商,在康复领域和医美领域成为中国领先供应商,正在探索海外市场以 及TMS治疗抑郁症技术及创新模式。 截至2025年3月31日，伟思医疗实现营业总收入9591.27万元，同比增长9.40%，实现归属净利润3322.01 万元，同比增长52.71%。流动比率、速动比率分别为7.579、7.341，资产负债率为8.47%。 8月15日收盘，伟思医疗当日上涨1.82%，成交额1.98亿元，换手率3.74%。从区间来看，该股近10个交 易日累计上涨22.0%。 资金流向方面，今日主力资金净流出546.86万元，占成交比2.76%，其中超大单净流入334.22万元，占 成交比1.69%。 ...

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 8月14日，沪深两融数据显示，伟思医疗获融资买入额0.36亿元，居两市第671位，当日融资偿还额0.48 亿元，净卖出1222.99万元。 最近三个交易日，12日-14日，伟思医疗分别获融资买入0.60亿元、0.54亿元、0.36亿元。 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Weisi Medical, which closed at 54.52 yuan with a decline of 2.64%, resulting in a rolling PE ratio of 46.03 times and a total market value of 5.221 billion yuan [1] - In comparison to the medical device industry, Weisi Medical's PE ratio is below the industry average of 55.76 times and the industry median of 39.14 times, ranking 82nd in the sector [1][2] - As of the first quarter of 2025, only one institution holds shares in Weisi Medical, with a total of 90,000 shares valued at 0.04 million yuan [1] Group 2 - Weisi Medical specializes in the research, production, and sales of medical devices, with key products including magnetic stimulation, electrical stimulation, electrophysiology, consumables and accessories, and laser radiofrequency [1] - The latest financial results for the first quarter of 2025 show that the company achieved a revenue of 95.9127 million yuan, representing a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, reflecting a year-on-year growth of 52.71%, with a gross profit margin of 66.65% [1]

金融界消息 截至2025年8月14日收盘，伟思医疗（688580）报收于54.52元，下跌2.64%，换手率4.9%， 成交量4.70万手，成交金额2.58亿元。 资金流向方面，今日主力资金净流出2692.66万元，占比成交额10.42%。其中，超大单净流出166.32万 元、占成交额0.64%，大单净流出2526.33万元、占成交额9.78%，中单净流出流入556.05万元、占成交 额2.15%，小单净流入2136.61万元、占成交额8.27%。 伟思医疗最新一期业绩显示，截至2025一季报，公司营业总收入9591.27万元、同比增长9.40%，归属净 利润3322.01万元，同比增长52.71%，扣非净利润3053.83万元，同比增长58.96%，流动比率7.579、速动 比率7.341、资产负债率8.47%。 天眼查商业履历信息显示，南京伟思医疗科技股份有限公司，成立于2001年，位于南京市，是一家以从 事医药制造业为主的企业。企业注册资本9577.1288万人民币，实缴资本5126万人民币。公司法定代表 人为王志愚。 通过天眼查大数据分析，南京伟思医疗科技股份有限公司共对外投资了11家企业，参与招投标 ...

Industry Overview - On August 14, the medical device industry experienced a decline of 2.45% with a net outflow of 1.74 billion yuan in principal funds [1] - Among the component stocks, 13 increased while 87 decreased [1] Major Fund Outflows - The companies with the highest net outflows of principal funds included: - Kehua Bio (29.96 million yuan) - Baolait (29.32 million yuan) - Shangrong Medical (28.74 million yuan) - Weisi Medical (26.93 million yuan) - ST Kelly (26.25 million yuan) [1] Notable Stock Performance - Key stocks with significant movements included: - Sainuo Medical: Latest price 30.43, up 3.05%, with a net inflow of 164 million yuan (7.25% of total) [1] - Botao Bio: Latest price 45.13, up 19.99%, with a net inflow of 543.74 thousand yuan (12.47% of total) [1] - Yuyue Medical: Latest price 35.67, down 0.17%, with a net inflow of 49.30 thousand yuan (12.91% of total) [1] - Kefu Medical: Latest price 40.58, up 6.99%, with a net inflow of 470.40 thousand yuan (14.3% of total) [1] - Huatai Medical: Latest price 290.99, down 2.03%, with a net inflow of 297.47 thousand yuan (9.99% of total) [1] - Aohua Endoscopy: Latest price 49.14, down 7.79%, with a net inflow of 2363.53 thousand yuan (10.09% of total) [1] - Meihua Medical: Latest price 20.94, up 3.05%, with a net inflow of 2316.72 thousand yuan (4.81% of total) [1] - Wanfu Bio: Latest price 24.28, down 0.92%, with a net inflow of 184.26 thousand yuan (5.48% of total) [1] - Zhijiang Bio: Latest price 25.24, up 4.87%, with a net inflow of 1420.31 thousand yuan (5.07% of total) [1] - Mairande: Latest price 51.64, up 1.06%, with a net inflow of 1335.64 thousand yuan (2.42% of total) [1]

来源:金融界 伟思医疗8月13日股价报收56.00元，较前一交易日上涨0.14元，涨幅0.25%。当日成交量为48657手，成 交金额达2.7亿元，换手率为5.08%。 从资金流向来看，伟思医疗8月13日主力资金净流出1459.31万元，近五日累计净流出888.30万元。当日 医疗设备板块整体表现不佳，多只相关个股出现下跌。 风险提示：股市有风险，投资需谨慎。 伟思医疗属于医疗器械板块，公司主营业务为医疗设备的研发、生产和销售。公司产品涵盖多个医疗领 域，包括康复医疗设备、手术器械等。 ...

通过天眼查大数据分析，南京伟思医疗科技股份有限公司共对外投资了11家企业，参与招投标项目1239 次，知识产权方面有商标信息173条，专利信息291条，此外企业还拥有行政许可166个。 金融界消息 截至2025年8月13日收盘，伟思医疗（688580）报收于56.0元，上涨0.25%，换手率5.08%， 成交量4.87万手，成交金额2.70亿元。 来源：金融界 资金流向方面，今日主力资金净流出1459.31万元，占比成交额5.4%。其中，超大单净流出387.66万 元、占成交额1.44%，大单净流出1071.65万元、占成交额3.97%，中单净流出流入939.16万元、占成交 额3.48%，小单净流入520.15万元、占成交额1.93%。 伟思医疗最新一期业绩显示，截至2025一季报，公司营业总收入9591.27万元、同比增长9.40%，归属净 利润3322.01万元，同比增长52.71%，扣非净利润3053.83万元，同比增长58.96%，流动比率7.579、速动 比率7.341、资产负债率8.47%。 天眼查商业履历信息显示，南京伟思医疗科技股份有限公司，成立于2001年，位于南京市，是一家以从 事医药制 ...

（文章来源：每日经济新闻） 每经AI快讯，8月13日，医疗设备板块短线走低，麦澜德跌超7%，翔宇医疗、澳华内镜、鹿得医疗、伟 思医疗等跟跌。 ...

Group 1 - The core viewpoint is that the brain-computer interface (BCI) sector is experiencing significant activity and growth, driven by government policies aimed at fostering innovation and development in the industry [1][2]. - The Ministry of Industry and Information Technology and six other departments have issued implementation opinions to promote the innovation and development of the BCI industry, with key technological breakthroughs expected by 2027 [1]. - By 2030, the BCI industry is projected to have a significantly enhanced innovation capability, with the establishment of a reliable industrial system and the cultivation of globally influential leading enterprises [1]. Group 2 - The BCI technology is positioned at the forefront of the integration of life sciences and information sciences, facilitating collaborative interaction between biological intelligence and machine intelligence [2]. - Continuous innovation in BCI technology is leading to rapid industrial growth, with the potential for disruptive breakthroughs and the deep integration of technological and industrial innovation [2]. - The market for BCI is expected to expand rapidly as domestic companies move towards commercial application and industrialization, supported by advancements in upstream technologies [2].

Company Overview - Weisi Medical's stock closed at 55.86 yuan, up 5.40%, with a rolling PE ratio of 47.16, marking a new low in 340 days, and a total market capitalization of 5.35 billion yuan [1] - The company operates in the medical device sector, focusing on the research, production, and sales of medical devices, including magnetic stimulation, electrical stimulation, electrophysiology, consumables, and laser radiofrequency products [1] Financial Performance - For Q1 2025, Weisi Medical reported revenue of 95.91 million yuan, a year-on-year increase of 9.40%, and a net profit of 33.22 million yuan, reflecting a year-on-year growth of 52.71%, with a gross profit margin of 66.65% [1] Shareholder Information - As of March 31, 2025, Weisi Medical had 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 57.51, with a median of 41.25, placing Weisi Medical at the 83rd position in the industry ranking [1] - The industry average PE ratio is 57.51, while the median is 41.25, indicating that Weisi Medical's PE ratio is below the industry average [2]